TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and Tolerance
TGF-β 对粘膜和全身 T 细胞免疫和耐受的调节
基本信息
- 批准号:10920182
- 负责人:
- 金额:$ 215.03万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Animal ModelAntigensApoptosisApoptoticAttentionAutoimmune DiseasesAutoimmunityBasic ScienceCellsCommunicable DiseasesDendritic CellsDevelopmentDiseaseFOXP3 geneGenerationsGenesGenetically Engineered MouseGlycolysisGoalsIL2RA geneImmune ToleranceImmunityImmunosuppressionInflammationInsulin-Dependent Diabetes MellitusKnockout MiceKnowledgeLymphocyteLymphoidLymphoid TissueMacrophageMalignant NeoplasmsMannoseMediatingMetabolismMissionMolecularMucous MembraneNational Institute of Dental and Craniofacial ResearchOral cavityOral mucous membrane structurePathogenesisPathway interactionsPeptidesPeripheralPlayProductionPulmonary InflammationRegulationRegulatory T-LymphocyteResearchRoleSepsisSignal TransductionSystemT cell regulationT-LymphocyteTherapeutic InterventionThymus GlandTimeTransforming Growth Factor betaTransforming Growth Factor beta Receptorsautoimmune inflammationdesignhuman diseaseinterestintraepithelialmalignant mouth neoplasmmouse modeltranscription factortumorwound healing
项目摘要
Our research interest is to elucidate mechanisms of TGF-beta regulation of mucosal and systemic T cell immunity and tolerance, in order to offer targets to manipulate T cell immunity versus tolerance in animal models to develop potential therapies for relevant human diseases such as autoimmunity, cancer and infectious diseases. Specifically we would like to understand (1) how TGF-beta is involved in the function and development of CD4+CD25+ T regulatory cells (Treg) in mucosal and other lymphoid tissues, (2) how TGF-beta regulates T programmed cell death and the consequent immune tolerance, (3) how TGF-beta signal transduction and TGF-beta production in mucosal T cells are regulated, and (4) The cellular and molecular mechanisms of TGF-beta regulation of oral mucosal intraepithelial lymphocytes (IELs). Recently, we have focused on the isolation and characterization of CD4+CD25+ T regulatory cells from normal and genetically engineered mice and dissected the involvement of TGF-beta in immunosuppression mediated by T regulatory cells. Importantly, we have also identified that TGF-beta is a critical factor in the conversion of naive CD4+CD25- peripheral T cells to CD4+CD25+ T regulatory cells through induction of Foxp3, a master gene for T regulatory cell development. This finding not only has significant impact on understanding the generation of CD4+CD25+ regulatory T cells, but also makes it possible for the first time to design strategies to embellish the limited and/or inadequate numbers of T regulatory cells in the periphery, as needed, for therapeutic intervention in autoimmune diseases and inflammation. In addition, with the T-cell specific conditional TGF-beta receptor I knockout mice, we have shown that TGF-beta signaling is also critical for the development and generation of natural Foxp3+ Tregs in the thymus. In related studies, we have demonstrated that combination of clearance of apoptotic T cells by macrophages and immature dendritic cells with administration of autoantigenic peptide leads to generation of antigen-specific Tregs that in turn suppress autoimmunity and induce long-term immune tolerance. Furthermore, we have also discovered that D-mannose induces Treg cells and suppresses type I diabtes and lung inflammation in mouse models. Moreover, we have discovered two transcription factors DBP and E2F8 play an opposite functions in the differentiation of anti-tumor Th9 cells. We have also revealed that TGF-beta uncouples glycolysis and inflammation in macrophages and controls the survival during sepsis. Our immediate next steps are to decipher the molecular pathway(s) by which TGF-beta induces Foxp3 expression to define how CD4+CD25+ T cells are developed in and out of mucosal lymphoid systems, as well as to begin to resolve the mystery of TGF-beta's role in T regulatory cell mediated immune tolerance. We also intend to apply the knowledge obtained from our basic research in animal models to develop potential therapy for relevant human diseases including inflammation/autoimmune diseases, cancer and infectious diseases, with special attention to NIDCR mission relevant diseases such as wound healing, oral cavity associated inflammation and oral cancer.
我们的研究兴趣是阐明TGF-β调节粘膜和系统性T细胞免疫和耐受的机制,以提供在动物模型中操纵T细胞免疫与耐受的靶点,从而开发用于相关人类疾病如自身免疫、癌症和感染性疾病的潜在疗法。具体而言,我们希望了解(1)TGF-β如何参与粘膜和其他淋巴组织中CD 4 + CD 25 + T调节细胞(Treg)的功能和发育,(2)TGF-β如何调节T细胞程序性死亡和随后的免疫耐受,(3)如何调节粘膜T细胞中的TGF-β信号转导和TGF-β产生,口腔黏膜上皮内淋巴细胞(IELs)TGF-β调节的细胞和分子机制。 最近,我们集中于从正常和基因工程小鼠中分离和鉴定CD 4 + CD 25 + T调节细胞,并剖析了TGF-β参与T调节细胞介导的免疫抑制。重要的是,我们还确定了TGF-β是通过诱导Foxp 3(T调节细胞发育的主基因)将初始CD 4 + CD 25-外周T细胞转化为CD 4 + CD 25 + T调节细胞的关键因子。这一发现不仅对理解CD 4 + CD 25+调节性T细胞的产生具有重大影响,而且还首次使设计策略以根据需要修饰外周中有限和/或不足数量的T调节性细胞成为可能,用于自身免疫性疾病和炎症的治疗干预。 此外,通过T细胞特异性条件性TGF-β受体I敲除小鼠,我们已经表明TGF-β信号传导对于胸腺中天然Foxp 3 + TcB的发育和产生也是至关重要的。在相关研究中,我们已经证明,巨噬细胞和未成熟树突状细胞清除凋亡T细胞与给予自身抗原肽的组合导致抗原特异性T细胞的产生,从而抑制自身免疫并诱导长期免疫耐受。此外,我们还发现D-甘露糖在小鼠模型中诱导Treg细胞并抑制I型糖尿病和肺部炎症。 此外,我们还发现两种转录因子DBP和E2 F8在抗肿瘤Th 9细胞的分化中起相反的作用。我们还发现,TGF-β解偶联糖酵解和巨噬细胞中的炎症,并控制脓毒症期间的存活。我们的下一步是破译TGF-β诱导Foxp 3表达的分子途径,以确定CD 4 + CD 25 + T细胞如何在粘膜淋巴系统内外发育,以及开始解决TGF-β在T调节细胞介导的免疫耐受中的作用之谜。我们还打算将从动物模型基础研究中获得的知识应用于开发相关人类疾病的潜在治疗方法,包括炎症/自身免疫性疾病,癌症和感染性疾病,特别关注NIDCR使命相关疾病,如伤口愈合,口腔相关炎症和口腔癌。
项目成果
期刊论文数量(66)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41].
“口腔癌衍生的外泌体 NAP1 通过 IRF-3 途径增强自然杀伤细胞的细胞毒性”的勘误 [Oral Oncol.
- DOI:10.1016/j.oraloncology.2018.01.007
- 发表时间:2018
- 期刊:
- 影响因子:4.8
- 作者:Wang,Yingnan;Qin,Xing;Zhu,Xueqin;Chen,Wanjun;Zhang,Jianjun;Chen,Wantao
- 通讯作者:Chen,Wantao
The DNA-binding inhibitor Id3 regulates IL-9 production in CD4(+) T cells.
- DOI:10.1038/ni.3252
- 发表时间:2015-10
- 期刊:
- 影响因子:30.5
- 作者:Nakatsukasa H;Zhang D;Maruyama T;Chen H;Cui K;Ishikawa M;Deng L;Zanvit P;Tu E;Jin W;Abbatiello B;Goldberg N;Chen Q;Sun L;Zhao K;Chen W
- 通讯作者:Chen W
Prestimulation of CD2 confers resistance to HIV-1 latent infection in blood resting CD4 T cells.
- DOI:10.1016/j.isci.2021.103305
- 发表时间:2021-11-19
- 期刊:
- 影响因子:5.8
- 作者:He S;Guo J;Fu Y;Spear M;Qin C;Fu S;Cui Z;Jin W;Xu X;Chen W;Shang H;Wu Y
- 通讯作者:Wu Y
The molecular mechanisms of Foxp3 gene regulation.
- DOI:10.1016/j.smim.2011.06.005
- 发表时间:2011-12
- 期刊:
- 影响因子:7.8
- 作者:Maruyama T;Konkel JE;Zamarron BF;Chen W
- 通讯作者:Chen W
TGF-beta1 on osteoimmunology and the bone component cells.
- DOI:10.1186/2045-3701-3-4
- 发表时间:2013-01-15
- 期刊:
- 影响因子:7.5
- 作者:Kasagi S;Chen W
- 通讯作者:Chen W
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wanjun Chen其他文献
Wanjun Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wanjun Chen', 18)}}的其他基金
Immunotherapy of inflammation, autoimmune disease and cancer
炎症、自身免疫性疾病和癌症的免疫治疗
- 批准号:
10920187 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
TGF-beta Regulation of Mucosal and Systemic T Cell Immun
TGF-β 对粘膜和全身 T 细胞免疫的调节
- 批准号:
6966385 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and Tolerance
TGF-β 对粘膜和全身 T 细胞免疫和耐受的调节
- 批准号:
7967013 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and Tolerance
TGF-β 对粘膜和全身 T 细胞免疫和耐受的调节
- 批准号:
8929662 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and Tolerance
TGF-β 对粘膜和全身 T 细胞免疫和耐受的调节
- 批准号:
7733895 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
Immunotherapy of inflammation, autoimmune disease and cancer
炎症、自身免疫性疾病和癌症的免疫治疗
- 批准号:
10487166 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and Tolerance
TGF-β 对粘膜和全身 T 细胞免疫和耐受的调节
- 批准号:
8553316 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
TGF-beta Regulation of Mucosal and Systemic T Cell Immun
TGF-β 对粘膜和全身 T 细胞免疫的调节
- 批准号:
7318843 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and Tolerance
TGF-β 对粘膜和全身 T 细胞免疫和耐受的调节
- 批准号:
7593351 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
TGF-beta Regulation of Mucosal and Systemic T Cell Immunity and Tolerance
TGF-β 对粘膜和全身 T 细胞免疫和耐受的调节
- 批准号:
10261201 - 财政年份:
- 资助金额:
$ 215.03万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 215.03万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 215.03万 - 项目类别: